Takeda Pharmaceutical Company Limited [4502.T]
TOKYO, May 19 (Pulse News Wire) – Takeda Pharmaceutical Company Limited (4502.T) reported an unfavorable verdict in a US antitrust case involving its drug AMITIZA® (lubiprostone). On May 18, 2026 (Eastern Time), a federal court in Massachusetts ruled against Takeda, awarding plaintiffs $[884,943,990] million in compensatory damages.
This amount could triple due to statutory penalties, potentially affecting the company's financial statements for the fiscal year ending March 31, 2026. Takeda plans to adjust its financial projections based on further legal proceedings and intends to file revised financial reports with the Tokyo Stock Exchange once the final liability amount is determined. In response to the ruling, Takeda stated it would contest the decision through appeals and post-verdict motions.
The company believes the claims lack merit and maintains its stance that the settlement agreement was compliant with Hatch-Waxman Act regulations. AMITIZA, approved in 2006 for treating chronic idiopathic constipation in adults, is no longer marketed by Takeda, which ended its licensing arrangement with Sucampo Pharmaceuticals in March 2024. The company expects to refine its cash flow forecasts but does not anticipate significant impacts on its 2026 performance guidance until further analysis is complete.
🟢 Confidence: High AI-translated content.